Sign up Australia
Proactive Investors - Run By Investors For Investors

Theralase Technologies' lead compound shown to destroy lung cancer

The latest data comes from pre-clinical research carried out by Dr Kazuhiro Yasufuku and his team in Toronto
Theralase Technologies' lead compound shown to destroy lung cancer
In 2016, an estimated 20,800 Canadians died from lung cancer, representing 26% of all cancer deaths

Shares in Theralase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) were lifted 4% on Tuesday as there was more good news for its lead cancer compound TLD-1433, which has been shown to destroy certain lung cancers.

The drug is what's called a light activated photo dynamic compound (PDC), and is also currently being studied in a bladder cancer trial.

This latest data comes from pre-clinical research carried out by Dr Kazuhiro Yasufuku and his team in Toronto  on its affect on lung squamous cell carcinoma, large cell lung cancer carcinoma and lung adeno carcinoma, all of which are non-small cell lung cancers (NSCLC), which accounts for 85% of all cases of the killer disease.

The study showed that TLD-1433, when combined with transferrin to form Rutherrin can localize to and destroy the various forms of lung cancer - in test tubes and live  model experiments.

In simple terms, this is because it can attach itself to transferrin receptor (Tf-R), which is prevalent in cancer growth, and not affect healthy tissue.

"These results support the hypothesis that safety and efficacy of PDT therapy will be enhanced due to improved localization to lung tumours versus healthy lung tissue and the selective irradiation of the cancer lesions by strategic placement of the laser light source," said Dr Yasufuku.

"The selectivity data also suggests that when an efficacious level of Rutherrintrademark is delivered and then light activated, a high kill rate of lung cancer may be achieved in patients. This hypothesis will be tested in future preclinical work using orthotopic animal models and if successful, then tested clinically in a Phase Ib human NSCLC clinical trial."

A delighted Roger Dumoulin-White, Theralase chief executive, added: "The quality of this research lays the ground work for further preclinical experiments and if proven successful the commencement of a Phase Ib clinical study for NSCLC, the leading cause of cancer related death."

Shares gained 4.35% to C$0.48.



Giles_55af4ddca6481.jpg


Register here to be notified of future TLT Company articles
View full TLT profile View Profile

Theralase Technologies Inc. Timeline

Related Articles

gas-pipelines---great-pic.jpg
August 10 2017
The Power and Electromechanical (P&EM) business's unaudited backlog was $19.2mln as at end June
picture of trading screens
November 30 2017
Tavistock’s optimism is based on the surge of money into its seven discretionary funds that trade under the Acumen brand.
Remote meetings camera
July 26 2017
LoopUp shares, which floated at a pound a pop in August 2016, were up another 9% today to after the remote meetings enabler said it had a robust first half

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use